SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunoGen
IMGN 31.230.0%Feb 26 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: misti30 who wrote (3017)4/14/2000 12:57:00 AM
From: Gary Mohilner  Read Replies (2) of 5665
 
Misti,

I think a number of good things could happen by June.

One reason is June is the end of IMGN's fiscal year, so I believe there'll be a big push to finish partnerships and make any new drug announcements prior to the end of June so they can be reflected in the Annual Report.

Their Partnership with BCHE should be renewed by the end of June as well. If it's not renewed BCHE would lose the rights to the screens that have already been provided, and as we've heard, they've developed drugs using those screens, so a renewal of the partnership is almost a certainty.

Finally, by June we'll be at the six month point on the Phase 1/2 Trial. They may not have yet achieved complete remissions by then, but I strongly believe that efficacy will have been demonstrated by then, and I think they'll tell us so.

Gary
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News